Diamines & Chemicals returned to profitability in its standalone results for Q1FY26, reporting a net profit of ₹27.32 lakh compared to a net loss of ₹209.40 lakh in the quarter ended March 31, 2026. The turnaround was supported by a 54.7% sequential rise in revenue from operations to ₹1,436.85 lakh and a significant reduction in other expenses. The Board of Directors approved the unaudited financial results on August 5, 2026, alongside a strategic investment plan and operational updates regarding its ongoing project.

The Board approved an additional investment of ₹40 crore in its wholly owned subsidiary, DACL Fine Chem Limited. This capital infusion will be met through cash accruals and other liquid funds available with the company, structured as unsecured loans, debentures, equity, or preference shares. The funds are designated for meeting relevant capital and operational expenditure requirements of the subsidiary, subject to local and regulatory approvals.

Financial Performance

Standalone revenue from operations stood at ₹1,436.85 lakh for the quarter ended June 30, 2026, up from ₹928.72 lakh in the previous quarter. Other income declined to ₹68.07 lakh from ₹107.81 lakh. Total income reached ₹1,504.92 lakh. Expenses were managed effectively, with total expenses decreasing to ₹1,477.60 lakh from ₹1,330.21 lakh in the prior quarter, primarily due to a drop in other expenses to ₹382.81 lakh from ₹784.54 lakh year-on-year. Cost of material consumed was ₹782.72 lakh.

On a consolidated basis, the group reported a net loss of ₹10.33 lakh for the quarter, narrowing significantly from a loss of ₹241.57 lakh in the previous quarter. Consolidated revenue from operations was ₹1,437.20 lakh. The loss was partly attributed to a share of loss of ₹5.57 lakh from its associate, KLJ Organic Diamines Limited. Consolidated total comprehensive income stood at ₹117.89 lakh, driven by gains on equity instruments measured at fair value through other comprehensive income (FVTOCI).

Operational Updates

The Board provided an update on the company’s current project, noting substantial completion in mechanical erection, utilities integration, instrumentation, electrical systems, and process commissioning. All major equipment and auxiliary systems have been installed. While initial parts of the process showed satisfactory performance during trial operations, commercial production has not yet commenced due to ongoing optimization of the distillation process in the downstream section.

Additionally, the Board approved the discontinuation of the Trading Division in the farming industry (Fruits & Vegetables segment) with immediate effect, citing no business activity in this segment since last year. The company also allotted 2,127 equity shares of face value ₹10 each to eligible employees upon exercise of stock options under the DACL-ESOP 2021 scheme, increasing the paid-up equity share capital to ₹10,05,55,190.

What the Numbers Show

The most significant aspect of this quarter is the divergence between standalone and consolidated performance. While the standalone entity achieved a net profit of ₹27.32 lakh, the consolidated group remained in the red with a loss of ₹10.33 lakh. This discrepancy highlights the drag from the associate company, KLJ Organic Diamines Limited, which contributed a share of loss of ₹5.57 lakh. Furthermore, the standalone result benefited from a tax credit of nil current tax but included deferred tax adjustments in prior periods; however, the immediate turnaround in standalone PAT suggests improved operational efficiency in the core Speciality Chemicals segment, which generated a pre-tax profit of ₹29.68 lakh compared to a loss of ₹283.96 lakh in the previous quarter.

The Nomination and Remuneration Committee (NRC) of diamines & chemicals approved the grant of 3000 stock options to eligible employees under the DACL Employee Stock Option Plan 2021 (ESOP-2021). The decision was taken during a meeting held on August 04, 2026, marking the eighth tranche of grants under the scheme. This move aims to align employee interests with long-term shareholder value through equity participation.

Grant Details and Terms

The company disclosed the grant pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR') and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023. The ESOP-2021 was originally approved by shareholders on July 20, 2021, in compliance with the SEBI (Share Based Employee Benefits) Regulations, 2014, which were later replaced by the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ('SEBI SBEBSE'). The plan was subsequently updated by the NRC and the Board on May 11, 2022.

Each option carries the right to apply for and be allotted one equity share of ₹ 10 face value. The exercise price for eligible employees is determined based on their appointment terms, allowing for grants either at the face value of ₹ 10 or at 50% of the market price, defined as the closing price of the previous trading day from the grant date.

Scheme Status and Limits

The total number of options that can be granted under the ESOP Plan is capped at 2,00,000, representing 2% of the total paid-up share capital. Each exercised option converts into one fully paid-up equity share. The current grant of 3000 options falls within this limit.

As per the disclosure, historical activity under the scheme includes the exercise of 750 options, which resulted in money realized of ₹ 7500. Additionally, 9643 options have lapsed. The total number of shares outstanding following these exercises stands at 10,053,392. There have been no variations to the terms of the options, and the newly granted 3000 options are yet to be exercised, meaning they do not currently impact diluted earnings per share.